Protagonist Therapeutics, Inc.
PTGX
$155.10
$3.682.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 82.91M | -114.71M | -130.15M | 45.91M | 52.04M |
| Total Depreciation and Amortization | 1.54M | 1.45M | 1.28M | 2.68M | 1.73M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 46.04M | 42.18M | 40.33M | 35.72M | 35.31M |
| Change in Net Operating Assets | 705.00K | -45.55M | 146.21M | -18.85M | -49.54M |
| Cash from Operations | 131.20M | -116.64M | 57.67M | 65.47M | 39.54M |
| Capital Expenditure | -615.00K | -1.26M | -1.59M | -1.76M | -2.44M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 79.34M | 137.22M | -47.74M | -105.12M | -254.58M |
| Cash from Investing | 78.72M | 135.96M | -49.33M | -106.87M | -257.03M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 41.61M | 34.80M | 23.34M | 24.54M | 30.93M |
| Repurchase of Common Stock | 0.00 | 0.00 | -479.00K | -479.00K | -479.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 41.61M | 34.80M | 22.86M | 24.06M | 30.45M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 251.53M | 54.12M | 31.20M | -17.35M | -187.04M |